The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Don't forget imminent IB stroke launch, auto segmentation & Gad free projects. For newcomers who maybe haven't looked yet, I would encourage some research on these & not just SC sale. Game changing potential here. I think another RNS either this or next week, though not necessarily related to these (CB)!? DYOR
Problem with previous link - try this one
https://t.co/OdondSVSuR?amp=1
No RNS needed as not specific to IQAI but as they say its 'huge' news.
IQAI research group is on the following telegram link:
https://t.me/c/1242524459/897
https://youtu.be/5X4Zz1V3KNU
Apologies if this has been added recently but worth a review...
Old Tramp - I'm no Clinton Baptiste but my prediction is we get another RNS within 2 weeks & a second within 3 weeks
IQAIs constant development of existing tech into new areas + new tech ensures a pipeline of products that are extremely valuable in the right hands. That is why the sale of SC with tie in to a major is more about the collaborative agreement than up front cash. I think SC although very valuable is their least valuable asset by a significant margin - IB stroke is imminent & Gad free just around the corner - both addressing huge markets.
You have to think how much these products are potentially worth. Taking Gad free for IB alone (the brain imaging DL model is built & currently being tested for its efficacy) - Gad free as mentioned many times costs the US $1.2Billion a year alone excluding time & manpower costs. What size of contracts would IB achieve if they can eliminate its use (with patent pending for the brain & other organs). If they tap a small portion of this market it would transform this smallcap - with the help of a major that could be a much larger portion. DYOR
I like to keep in mind what news is due so i've listed what i think is likely over the short term. I don't think the order & timings of arrival really matter but we have good estimates for some of the news so I am having an educated guess on a couple.
Telemedicine - within the month
IB Stroke - first week of October
Gad free update - Q4
Grant - October
Stonechecker Sale - anytime??
Other applications for IB update - expecting this could arrive first!?
Gad Free Patent application - anyone's guess but was submitted Oct 2018 - the important fact is it has been applied for.
Its a hot topic at the moment & even ignoring the obvious time & agent costs associated with using Gad, with the litigious culture in the US , an alternative to its use will be taken very seriously & would expect a very rapid uptake. IQAI are on the cusp of achieving this with patent pending. DYOR
1.2 Billion spent a year in the US on Gadolinium agents alone - add cost savings on speed enhancements & the potential of litigation etc - success here will transform the company.
Telemedicine, SC sale, IB stroke product or one of the other 'exciting' new applications next..
Getting close now to IB stroke product release (due early Q4) - will be a huge addition to their suite of products & as clearance not required it will be straight to market + included on Arterys on-line AI platform. I would expect some other big news release before then though!?
Just for clarification Wolves it was 3.50 on the mid before news & today's is 4.50 on the mid & really all you are describing is the natural cycle of how any share behaves. No straight lines especially for small caps but more pronounced spikes on news (44M shares traded on the LOI for SC). This gives opportunities for all investors & traders alike but I believe with more concrete news ahead it will give a more sustained rise but each have to place their value on what's to come.
News expected from Telemedicine launch, SC sale, Gadolinium free update, IB stroke package + expanding IB into other areas all within a short period of time - plenty to look forward to here.
Agree DShox Gadolinium free project should not be overlooked - they have already reduced the need for double dose so saving 50% usage but are working on eliminating its use further if not to nil & if successful will also add huge value to the company.
Gadolinium free also fits nicely with their intention to get into telemedicine - as Dr Zaharchuck of Stanford Uni mentioned in the recent article shared by IQAI where he stated 'AI to enable lower or even no doses of gadolinium-based contract are also emerging as real wild cards but could revolutionise how we do imaging' -
IQAI are poised to be at the forefront of this revolution & it is going to happen very soon.
Looking solely at SC is a very myopic view of a much larger offering although will obviously help expedite these projects.
IMO whatever the cash price of Stonechecker, the deal looks to have many benefits that secure an extremely exciting future for IQAI.
The company will be in a strong cash position which will allow them to accelerate development of existing applications & springboard those to market + fund additional applications they have been alluding to.
SC should reach its full potential in the hands of a major & we will receive on-going royalties from this. I would expect having this relationship with a major will mean future developments will be closely monitored.
Even though the potential for SC is very large (especially if it goes to a major) the IB stroke package is targeting a market that is many times its size & as stated is on target for early release in Q4 (already FDA cleared).
I think Telemedicine news next which could be transformational on its own then Gadolinium update or SC sale.
A little patience hear should be richly rewarded. As ever DYOR.
A very good interview & alludes lot of exciting projects to come. Next should be Telemedicine launch which should be an immediate commercial project - the intention is to follow this up with another interview.
It will be exciting to see the growth within the existing commercial product suite & announcement of further partnerships + IB stroke package launch this quarter (already with FDA clearance).
It hasn't been announced yet as far as I can see but I contacted him recently and he mentioned it. I get the impression they are going to make a more concerted effort to communicate with the market & i suspect the timing has a lot to do with it as a lot of news to come. Think Michael Schmainda will be taking over from where David Smith left off in this respect.